Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies
Stat Med
.
2021 Dec 10;40(28):6235-6242.
doi: 10.1002/sim.8971.
Authors
Zachary R McCaw
1
,
Lu Tian
2
,
Jiawei Wei
3
,
Brian Lee Claggett
4
,
Frank Bretz
5
6
,
Garrett Fitzmaurice
7
8
,
Lee-Jen Wei
8
Affiliations
1
1600 Amphitheatre Parkway, Mountain View, California.
2
Department of Biomedical Data Science, Stanford University, Stanford, California.
3
Novartis Institutes for Biomedical Research Co., Shanghai, China.
4
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
5
Novartis Pharma AG, Basel, Switzerland.
6
Section for Medical Statistics, Medical University of Vienna, Vienna, Austria.
7
Laboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, Massachusetts.
8
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
PMID:
34783094
PMCID:
PMC8687139
DOI:
10.1002/sim.8971
No abstract available
Publication types
Research Support, N.I.H., Extramural
Grants and funding
R01 HL089778/HL/NHLBI NIH HHS/United States